Xtant Medical Holdings, Inc.
XTNTNYSE
$0.45
↑ +1.6%Jul 17 close · end-of-day
Price
1Y↓ -22.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$63.0M
Enterprise Value
$62.7M
P/E
45.0
P/S
0.5
P/B
1.3
EV/EBITDA
7.9
PEG
—
FCF Yield
12.3%
Dividend Yield
—
Revenue (TTM)
$121.9M
Net Income (TTM)
-$3.1M
Free Cash Flow (TTM)
$7.8M
Gross Margin
62.3%
Operating Margin
2.7%
Net Margin
-2.6%
ROE
-6.5%
ROIC
3.4%
Debt / Equity
0.2
Net Cash
$322,000.00
Return 1Y
-27.4%
Company profile
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and osteoinductive potential of human bone.
- CEO
- Sean E. Browne
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 120
- Headquarters
- Montana
- Website
- xtantmedical.com
Management & directors
- Schallenberger Mark A.Chief Operating Officer
- Neils Scott CCFO and Assistant Secretary
- Browne Sean EPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
XTNT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$20.9M↓ -36.5%
Diluted EPS-$0.02—
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $53.3M | $55.3M | $58.0M | $91.3M | $117.3M | $133.9M |
| Gross profit | $34.4M | $32.5M | $32.1M | $55.5M | $68.2M | $84.3M |
| Operating income | -$751,000.00 | -$3.9M | -$6.8M | -$10.2M | -$12.1M | $7.3M |
| Net income | -$7.0M | -$4.8M | -$8.5M | $660.00 | -$16,449.00 | $4,973.00 |
| Diluted EPS | -$0.25 | -$0.06 | -$0.09 | $0.01 | -$0.12 | $0.03 |
| Operating cash flow | -$731,000.00 | $439,000.00 | -$5.3M | -$9.5M | -$11.9M | $12.5M |
| Free cash flow | -$2.3M | -$1.7M | -$7.1M | -$11.0M | -$16.0M | $10.2M |
| Gross margin | 64.5% | 58.8% | 55.4% | 60.8% | 58.2% | 62.9% |
| Operating margin | -1.4% | -7.0% | -11.7% | -11.1% | -10.3% | 5.4% |
| Net margin | -13.2% | -8.8% | -14.6% | 0.0% | -0.0% | 0.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.9M | $27.9M | $31.5M | $32.9M | $35.4M | $33.3M | $32.4M | $20.9M |
| Gross profit | $18.6M | $16.3M | $16.0M | $20.2M | $24.3M | $22.0M | $17.8M | $12.0M |
| Operating income | -$2.9M | -$3.8M | -$1.9M | $1.1M | $4.6M | $2.5M | -$944,000.00 | -$2.9M |
| Net income | -$3.9M | -$5.0M | $13.3M | $58,000.00 | $3.5M | $1.3M | -$4.9M | -$3.1M |
| Diluted EPS | -$0.03 | -$0.04 | -$0.02 | $0.00 | $0.02 | $0.01 | $0.00 | -$0.02 |
| Operating cash flow | -$5.1M | -$1.7M | $665,000.00 | $1.3M | $1.3M | $4.6M | $5.4M | -$2.1M |
| Free cash flow | -$5.7M | -$3.8M | -$7,000.00 | $87,000.00 | $910,000.00 | $4.2M | $5.0M | -$2.3M |
| Gross margin | 62.1% | 58.4% | 50.9% | 61.5% | 68.6% | 66.1% | 54.9% | 57.3% |
| Operating margin | -9.8% | -13.5% | -6.0% | 3.2% | 13.1% | 7.6% | -2.9% | -14.0% |
| Net margin | -12.9% | -18.0% | 42.1% | 0.2% | 10.0% | 3.9% | -15.2% | -14.8% |
Company news
May 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-15 | Schallenberger Mark A.· Chief Operating Officer | Tax withholding | 7,709 | $0.58 | $4,471.22 | filing |
| 2026-01-15 | Neils Scott C· CFO and Assistant Secretary | Tax withholding | 8,084 | $0.65 | $5,254.60 | filing |
| 2025-11-15 | Vizirgianakis Stavros G. | Award | 553,797 | $0.00 | $0.00 | filing |
| 2025-11-15 | Beeson Jonn R. | Award | 158,228 | $0.00 | $0.00 | filing |
| 2025-11-15 | BAKEWELL JOHN K | Award | 158,228 | $0.00 | $0.00 | filing |
| 2025-11-15 | Lipschultz Tyler | Award | 158,228 | $0.00 | $0.00 | filing |
| 2025-11-15 | Browne Sean E· President and CEO | Award | 394,937 | $0.00 | $0.00 | filing |
| 2025-11-15 | Schallenberger Mark A.· Chief Operating Officer | Award | 292,253 | $0.00 | $0.00 | filing |
| 2025-11-15 | Neils Scott C· CFO and Assistant Secretary | Award | 263,291 | $0.00 | $0.00 | filing |
| 2025-11-15 | JAIN ABHINAV | Award | 158,228 | $0.00 | $0.00 | filing |
| 2025-11-15 | BAKEWELL JOHN K | Award | 158,228 | $0.00 | $0.00 | filing |
| 2025-08-15 | Neils Scott C· CFO | Tax withholding | 34,131 | $0.63 | $21,502.53 | filing |
| 2025-08-15 | Browne Sean E· President and CEO | Tax withholding | 10,605 | $0.63 | $6,681.15 | filing |
Latest 13 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.